The Liquid Biopsy in the Management of Colorectal Cancer: An Overview
Tóm tắt
Từ khóa
Tài liệu tham khảo
GBD 2017 Colorectal Cancer Collaborators (2019). The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 4, 913–933.
Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492
Bishehsari, 2014, Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention, World J. Gastroenterol., 20, 6055, 10.3748/wjg.v20.i20.6055
Hui, L. (2018). Quantifying the effects of aging and urbanization on major gastrointestinal diseases to guide preventative strategies. BMC Gastroenterol., 18.
(2020, July 14). Cancer Facts & Figures 2020|American Cancer Society. Available online: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html.
Nakayama, 2013, Current Options for the Diagnosis, Staging and Therapeutic Management of Colorectal Cancer, Gastrointest. Tumors, 1, 25, 10.1159/000354995
Bender, 2019, Adjuvant therapy for stages II and III colon cancer: Risk stratification, treatment duration, and future directions, Curr. Oncol., 26, S43, 10.3747/co.26.5605
Pfeiffer, 2019, The changing face of treatment for metastatic colorectal cancer, Expert Rev. Anticancer Ther., 19, 61, 10.1080/14737140.2019.1543593
Moriarity, 2016, Current targeted therapies in the treatment of advanced colorectal cancer: A review, Ther. Adv. Med. Oncol., 8, 276, 10.1177/1758834016646734
Norcic, G. (2018). Liquid biopsy in colorectal cancer-current status and potential clinical applications. Micromachines, 9.
Vacante, 2018, Biomarkers in colorectal cancer: Current clinical utility and future perspectives, World J. Clin. Cases, 6, 869, 10.12998/wjcc.v6.i15.869
Palmirotta, R., Lovero, D., Cafforio, P., Felici, C., Mannavola, F., Pellè, E., Quaresmini, D., Tucci, M., and Silvestris, F. (2018). Liquid biopsy of cancer: A multimodal diagnostic tool in clinical oncology. Ther. Adv. Med. Oncol., 10.
Crowley, 2013, Liquid biopsy: Monitoring cancer-genetics in the blood, Nat. Rev. Clin. Oncol., 10, 472, 10.1038/nrclinonc.2013.110
Fernández-Lázaro, D., García Hernández, J.L., García, A.C., Córdova Martínez, A., Mielgo-Ayuso, J., and Cruz-Hernández, J.J. (2020). Liquid biopsy as novel tool in precision medicine: Origins, properties, identification and clinical perspective of cancer’s biomarkers. Diagnostics, 10.
Otero, 2018, Exosomes: Definition, role in tumor development and clinical implications, Cancer Microenviron., 11, 13, 10.1007/s12307-018-0211-7
Wong, 2019, Clinical significance of exosomes as potential biomarkers in cancer, World J. Clin. Cases, 7, 171, 10.12998/wjcc.v7.i2.171
Lampis, A., Ghidini, M., Ratti, M., Mirchev, M.B., Okuducu, A.F., Valeri, N., and Hahne, J.C. (2020). Circulating tumour DNAs and Non-Coding RNAs as liquid biopsies for the management of colorectal cancer patients. Gastrointest. Disord., 2.
Osumi, 2019, Clinical utility of circulating tumor DNA for colorectal cancer, Cancer Sci., 110, 1148, 10.1111/cas.13972
Mathai, R.A., Vidya, R.V.S., Reddy, B.S., Thomas, L., Udupa, K., Kolesar, J., and Rao, M. (2019). Potential utility of liquid biopsy as a diagnostic and prognostic tool for the assessment of solid tumors: Implications in the precision oncology. J. Clin. Med., 8.
Rubis, 2019, Liquid biopsies in cancer diagnosis, monitoring, and prognosis, Trends Pharmacol. Sci., 40, 172, 10.1016/j.tips.2019.01.006
Gold, 2015, Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology, J. Mol. Diagn., 17, 209, 10.1016/j.jmoldx.2015.02.001
Ding, Y., Li, W., Wang, K., Xu, C., Hao, M., and Ding, L. (2020, July 16). Perspectives of the Application of Liquid Biopsy in Colorectal Cancer. Available online: https://www.hindawi.com/journals/bmri/2020/6843180/.
Tsai, 2018, Prospective clinical study of circulating tumor cells for colorectal cancer screening, J. Clin. Oncol., 36, 556, 10.1200/JCO.2018.36.4_suppl.556
Bork, 2015, Circulating tumour cells and outcome in non-metastatic colorectal cancer: A prospective study, Br. J. Cancer, 112, 1306, 10.1038/bjc.2015.88
Gazzaniga, 2013, Circulating tumor cells in high-risk nonmetastatic colorectal cancer, Tumour Biol., 34, 2507, 10.1007/s13277-013-0752-9
Tsai, W.-S., Chen, J.-S., Shao, H.-J., Wu, J.-C., Lai, J.-M., Lu, S.-H., Hung, T.-F., Chiu, Y.-C., You, J.-F., and Hsieh, P.-S. (2016). Circulating tumor cell count correlates with colorectal neoplasm progression and is a prognostic marker for distant metastasis in non-metastatic patients. Sci. Rep., 6.
Musella, 2015, Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab, Int. J. Cancer, 137, 1467, 10.1002/ijc.29493
Krebs, 2015, Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer, Clin. Colorectal Cancer, 14, 115.e2, 10.1016/j.clcc.2014.12.006
Tie, 2016, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci. Transl. Med., 8, 346ra92, 10.1126/scitranslmed.aaf6219
Sun, 2018, Monitoring colorectal cancer following surgery using plasma circulating tumor DNA, Oncol. Lett., 15, 4365
Tie, 2015, Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer, Ann. Oncol., 26, 1715, 10.1093/annonc/mdv177
Tie, 2018, Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC), J. Clin. Oncol., 36, 3516, 10.1200/JCO.2018.36.15_suppl.3516
Grasselli, 2017, Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer, Ann. Oncol., 28, 1294, 10.1093/annonc/mdx112
Khan, 2018, Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study, Gut, 67, 1484, 10.1136/gutjnl-2017-314178
Flamini, 2006, Free DNA and carcinoembryonic antigen serum levels: An important combination for diagnosis of colorectal cancer, Clin. Cancer Res., 12, 6985, 10.1158/1078-0432.CCR-06-1931
Hao, 2014, Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer, Br. J. Cancer, 111, 1482, 10.1038/bjc.2014.470
Sun, J., Fei, F., Zhang, M., Li, Y., Zhang, X., Zhu, S., and Zhang, S. (2019). The role of mSEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer, 19.
Link, 2010, Fecal microRNAs as novel biomarkers for colon cancer screening, Cancer Epidemiol. Biomark. Prev., 19, 1766, 10.1158/1055-9965.EPI-10-0027
Ya, 2017, Serum miR-129 functions as a biomarker for colorectal cancer by targeting estrogen receptor (ER) β, Pharmazie, 72, 107
He, 2018, Low-level serum miR-24-2 is associated with the progression of colorectal cancer, Cancer Biomark., 21, 261, 10.3233/CBM-170321
Wang, Y., Chen, Z., and Chen, W. (2017). Novel circulating microRNAs expression profile in colon cancer: A pilot study. Eur. J. Med. Res., 22.
Toiyama, 2014, Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer, Ann. Surg., 259, 735, 10.1097/SLA.0b013e3182a6909d
Tang, Y., Zhao, Y., Song, X., Song, X., Niu, L., and Xie, L. (2019). Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer. J. Clin. Lab. Anal., 33.
Koga, 2013, Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test, Cancer Epidemiol. Biomark. Prev., 22, 1844, 10.1158/1055-9965.EPI-13-0512
Sazanov, 2017, Plasma and saliva miR-21 expression in colorectal cancer patients, J. Appl. Genet., 58, 231, 10.1007/s13353-016-0379-9
Fu, 2018, Circulating exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal cancer, Transl. Oncol., 11, 221, 10.1016/j.tranon.2017.12.012
Tsukamoto, 2017, Circulating exosomal MicroRNA-21 as a biomarker in each tumor stage of colorectal cancer, Oncology, 92, 360, 10.1159/000463387
Liu, 2016, Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer, Oncotarget, 7, 76250, 10.18632/oncotarget.12841
Yan, 2018, Exosomal miR-6803-5p as potential diagnostic and prognostic marker in colorectal cancer, J. Cell. Biochem., 119, 4113, 10.1002/jcb.26609
Liu, 2018, Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer, Cancer Epidemiol. Biomark. Prev., 27, 746, 10.1158/1055-9965.EPI-18-0067
Peng, 2018, Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer, J. Cell. Biochem., 120, 1457, 10.1002/jcb.27291
Jin, 2019, A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer, Cancer Chemother. Pharmacol., 84, 315, 10.1007/s00280-019-03867-6
Yagi, 2019, Plasma exosomal microRNA-125b as a monitoring biomarker of resistance to mFOLFOX6-based chemotherapy in advanced and recurrent colorectal cancer patients, Mol. Clin. Oncol., 11, 416
Wang, 2018, Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy, Cell Death Dis., 9, 1, 10.1038/s41419-018-1187-4
Li, 2017, MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis, Oncol. Rep., 38, 1383, 10.3892/or.2017.5828
Sun, 2019, The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis, Mol. Med. Rep., 20, 3583
Tang, 2019, LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc, Nat. Commun., 10, 3499, 10.1038/s41467-019-11447-8
Liu, 2016, Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer, Oncotarget, 7, 85551, 10.18632/oncotarget.13465
Liang, 2019, LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization, Cell Death Dis., 10, 829, 10.1038/s41419-019-2077-0
Barkun, 2018, Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations, World J. Gastroenterol., 24, 124, 10.3748/wjg.v24.i1.124
Marcuello, 2019, Circulating biomarkers for early detection and clinical management of colorectal cancer, Mol. Asp. Med., 69, 107, 10.1016/j.mam.2019.06.002
Cima, 2016, Tumor-derived circulating endothelial cell clusters in colorectal cancer, Sci. Transl. Med., 8, 345ra89, 10.1126/scitranslmed.aad7369
Bi, 2020, Circulating tumor DNA in colorectal cancer: Opportunities and challenges, Am. J. Transl. Res., 12, 1044
Wang, 2018, Circulating cell free DNA as the diagnostic marker for colorectal cancer: A systematic review and meta-analysis, Oncotarget, 9, 24514, 10.18632/oncotarget.25314
Luo, H., Zhao, Q., Wei, W., Zheng, L., Yi, S., Li, G., Wang, W., Sheng, H., Pu, H., and Mo, H. (2020). Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci. Transl. Med., 12.
Nian, 2017, Diagnostic accuracy of methylated SEPT9 for blood-based colorectal cancer detection: A systematic review and meta-analysis, Clin. Transl. Gastroenterol., 8, e216, 10.1038/ctg.2016.66
Cohen, 2018, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, 359, 926, 10.1126/science.aar3247
Hayder, 2018, Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation, Front. Endocrinol. Lausanne, 9, 402, 10.3389/fendo.2018.00402
Ragusa, 2012, Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors, J. Mol. Med., 90, 1421, 10.1007/s00109-012-0918-8
Chen, 2019, Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis, Open Biol., 9, 180212, 10.1098/rsob.180212
Heymann, 2019, Circulating tumor cells as a tool for assessing tumor heterogeneity, Theranostics, 9, 4580, 10.7150/thno.34337
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., Liu, J., Xu, H., and Wang, Z. (2014). Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: A meta-analysis. BMC Cancer, 14.
Bettegowda, 2014, Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies, Sci. Transl. Med., 6, 224ra24, 10.1126/scitranslmed.3007094
Dasari, A., Morris, V.K., Allegra, C.J., Atreya, C., Benson, A.B., Boland, P., Chung, K., Copur, M.S., Corcoran, R.B., and Deming, D.A. (2020). ctDNA applications and integration in colorectal cancer: An NCI Colon and Rectal–Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol., 1–14.
Osumi, H., Shinozaki, E., and Yamaguchi, K. (2020). Circulating tumor DNA as a novel biomarker optimizing chemotherapy for colorectal cancer. Cancers, 12.
Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat. Med., 21, 795, 10.1038/nm.3870
Khan, 2018, longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C Phase II colorectal cancer clinical trial, Cancer Discov., 8, 1270, 10.1158/2159-8290.CD-17-0891
Siravegna, 2019, Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer, Clin. Cancer Res., 25, 3046, 10.1158/1078-0432.CCR-18-3389
To, 2018, MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside, World J. Gastroenterol., 24, 2949, 10.3748/wjg.v24.i27.2949
Zhang, 2017, Prognostic value of high-expression of miR-17-92 cluster in various tumors: Evidence from a meta-analysis, Sci. Rep., 7, 8375, 10.1038/s41598-017-08349-4
Ma, 2018, miR-1290 Contributes to Colorectal Cancer Cell Proliferation by Targeting INPP4B, Oncol. Res., 26, 1167, 10.3727/096504017X15051741798389
Falzone, 2018, Integrated analysis of colorectal cancer microRNA datasets: Identification of microRNAs associated with tumor development, Aging Albany N. Y, 10, 1000, 10.18632/aging.101444
Ragusa, 2010, Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment, Mol. Cancer Ther., 9, 3396, 10.1158/1535-7163.MCT-10-0137
Nagano, 2011, No-nonsense functions for long noncoding RNAs, Cell, 145, 178, 10.1016/j.cell.2011.03.014
Zhang, X., Wang, W., Zhu, W., Dong, J., Cheng, Y., Yin, Z., and Shen, F. (2019). Mechanisms and Functions of Long Non-Coding RNAs at Multiple Regulatory Levels. Int. J. Mol. Sci., 20.
Siddiqui, 2019, Roles of long non-coding RNAs in colorectal cancer tumorigenesis: A Review, Mol. Clin. Oncol., 11, 167
He, Q., Long, J., Yin, Y., Li, Y., Lei, X., Li, Z., and Zhu, W. (2020). Emerging Roles of lncRNAs in the Formation and Progression of Colorectal Cancer. Front. Oncol., 9.
Han, 2015, Long noncoding RNAs: Novel players in colorectal cancer, Cancer Lett., 361, 13, 10.1016/j.canlet.2015.03.002
Luo, 2017, Long non-coding RNAs: A rising biotarget in colorectal cancer, Oncotarget, 8, 22187, 10.18632/oncotarget.14728
Valli, 2019, Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism, Mol. Cancer Res., 17, 1531, 10.1158/1541-7786.MCR-18-0315
Barbagallo, 2018, LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions, Mol. Ther. Nucleic Acids, 12, 229, 10.1016/j.omtn.2018.05.009
Beije, 2019, Incorporating liquid biopsies into treatment decision-making: Obstacles and possibilities, Drug Discov. Today, 24, 1715, 10.1016/j.drudis.2019.05.028
Kolenčík, D., Shishido, S.N., Pitule, P., Mason, J., Hicks, J., and Kuhn, P. (2020). Liquid Biopsy in Colorectal Carcinoma: Clinical Applications and Challenges. Cancers, 12.
Leers, 2020, Circulating tumor DNA and their added value in molecular oncology, Clin. Chem. Lab. Med. CCLM, 58, 152, 10.1515/cclm-2019-0436
Hong, 2013, Detecting circulating tumor cells: Current challenges and new trends, Theranostics, 3, 377, 10.7150/thno.5195
Mamdouhi, 2019, Fugitives on the run: Circulating tumor cells (CTCs) in metastatic diseases, Cancer Metastasis Rev., 38, 297, 10.1007/s10555-019-09795-4
Millner, 2013, Circulating tumor cells: A review of present methods and the need to identify heterogeneous phenotypes, Ann. Clin. Lab. Sci., 43, 295
Barrière, G., Tartary, M., and Rigaud, M. (2012). Epithelial mesenchymal transition: A new insight into the detection of circulating tumor cells. ISRN Oncol., 2012.
Castro-Giner, F., Gkountela, S., Donato, C., Alborelli, I., Quagliata, L., Ng, C.K.Y., Piscuoglio, S., and Aceto, N. (2018). Cancer diagnosis using a liquid biopsy: Challenges and expectations. Diagnostics, 8.
Elazezy, 2018, Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management, Comput. Struct. Biotechnol. J., 16, 370, 10.1016/j.csbj.2018.10.002
Fontanges, 2018, Clinical application of targeted next-generation sequencing for colorectal cancer patients: A multicentric Belgian experience, Oncotarget, 9, 20761, 10.18632/oncotarget.25099
Qin, 2019, Next-generation sequencing and its clinical application, Cancer Biol. Med., 16, 4, 10.20892/j.issn.2095-3941.2018.0055
Narayan, 2012, Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing, Cancer Res., 72, 3492, 10.1158/0008-5472.CAN-11-4037
Couraud, 2014, Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: A proof-of-concept study from BioCAST/IFCT-1002, Clin. Cancer Res., 20, 4613, 10.1158/1078-0432.CCR-13-3063
Fontanges, Q., De Mendonca, R., Salmon, I., Le Mercier, M., and D’Haene, N. (2016). Clinical application of targeted next generation sequencing for colorectal cancers. Int. J. Mol. Sci., 17.
Grada, 2013, Next-generation sequencing: Methodology and application, J. Investig. Dermatol., 133, e11, 10.1038/jid.2013.248
Ng, 2019, Genomics and metagenomics of colorectal cancer, J. Gastrointest. Oncol., 10, 1164, 10.21037/jgo.2019.06.04
Kim, 2011, Genetic-based biomarkers and next-generation sequencing: The future of personalized care in colorectal cancer, Pers. Med., 8, 331, 10.2217/pme.11.16
Wadapurkar, 2018, Computational analysis of next generation sequencing data and its applications in clinical oncology, Inform. Med. Unlocked, 11, 75, 10.1016/j.imu.2018.05.003
Rachiglio, 2016, Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma, Oncotarget, 7, 66595, 10.18632/oncotarget.10704
Mastroiaco, 2017, Next-generation sequencing: Recent applications to the analysis of colorectal cancer, J. Transl. Med., 15, 246, 10.1186/s12967-017-1353-y
Soda, 2019, Advanced liquid biopsy technologies for circulating biomarker detection, J. Mater. Chem. B, 7, 6670, 10.1039/C9TB01490J
Risberg, 2018, Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients, J. Mol. Diagn., 20, 883, 10.1016/j.jmoldx.2018.07.005
Hauch, 2018, Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma, Curr. Pathobiol. Rep., 6, 275, 10.1007/s40139-018-0180-z
Harouaka, 2014, Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications, Pharmacol. Ther., 141, 209, 10.1016/j.pharmthera.2013.10.004
Tamkovich, 2006, Circulating DNA and DNase activity in human blood, Ann. N. Y. Acad. Sci., 1075, 191, 10.1196/annals.1368.026
Siravegna, 2019, How liquid biopsies can change clinical practice in oncology, Ann. Oncol., 30, 1580, 10.1093/annonc/mdz227
Heitzer, 2019, Current and future perspectives of liquid biopsies in genomics-driven oncology, Nat. Rev. Genet., 20, 71, 10.1038/s41576-018-0071-5
Haselmann, 2018, Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA), Clin. Chem. Lab. Med., 56, 220, 10.1515/cclm-2017-0283
Vivancos, A., Aranda, E., Benavides, M., Élez, E., Gómez-España, M.A., Toledano, M., Alvarez, M., Parrado, M.R.C., García-Barberán, V., and Diaz-Rubio, E. (2019). Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Sci. Rep., 9.